Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research

키워드

참고문헌 (127)

1. McInnes IB, "The pathogenesis of rheumatoid arthritis", N Engl J Med, 365, pp.2205~2219 (2011)
2. Firestein GS, "Evolving concepts of rheumatoid arthritis", Nature, 423, pp.356~361 (2003)
3. Firestein GS, "Immunopathogenesis of rheumatoid arthritis", Immunity, 46, pp.183~196 (2017)
4. Nygaard G, "Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblastlike synoviocytes", Nat Rev Rheumatol, 16, pp.316~333 (2020)
5. Smolen JS, "Rheumatoid arthritis therapy reappraisal : strategies, opportunities and challenges", Nat Rev Rheumatol, 11, pp.276~289 (2015)
6. de Hair MJ, "Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need", Rheumatology(Oxford), 57, pp.1135~1144 (2018)
7. Singh JA, "Risk of serious infection in biological treatment of patients with rheumatoid arthritis : a systematic review and meta-analysis", Lancet, 386, pp.258~265 (2015)
8. Pundole X, "Cancer and rheumatoid rrthritis", Rheum Dis Clin North Am, 46, pp.445~462 (2020)
9. Robertshaw HJ, "Release of tumour necrosis factor alpha(TNFalpha)by TNFalpha cleaving enzyme(TACE)in response to septic stimuli in vitro", Br J Anaesth, 94, pp.222~228 (2005)
10. Kalliolias GD, "TNF biology, pathogenic mechanisms and emerging therapeutic strategies", Nat Rev Rheumatol, 12, pp.49~62 (2016)
11. Finsterbusch M, "Neutrophils recruited by chemoattractants in vivo induce microvascular plasma protein leakage through secretion of TNF", J Exp Med, 211, pp.1307~1314 (2014)
12. Zhang F, "Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry", Nat Immunol, 20, pp.928~942 (2019)
13. 정연관, "Osteoclasts in the Inflammatory Arthritis: Implications for Pathologic Osteolysis", Immune Network, 19(1), pp.1~13 (2019), 대한면역학회[DOI]
14. Farrugia M, "The role of TNF-α in rheumatoid arthritis : a focus on regulatory T cells", J Clin Transl Res, 2, pp.84~90 (2016)
15. McInnes IB, "Cytokines in rheumatoid arthritis-shaping the immunological landscape", Nat Rev Rheumatol, 12, pp.63~68 (2016)
16. Asquith DL, "Animal models of rheumatoid arthritis", Eur J Immunol, 39, pp.2040~2044 (2009)
17. Williams RO, "Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis", Proc Natl Acad Sci U S A, 89, pp.9784~9788 (1992)
18. Guo Q, "Rheumatoid arthritis : pathological mechanisms and modern pharmacologic therapies", Bone Res, 6, pp.15~ (2018)
19. Akiho H, "Promising biological therapies for ulcerative colitis : a review of the literature", World J Gastrointest Pathophysiol, 6, pp.219~227 (2015)
20. Elliott MJ, "Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha", Arthritis Rheum, 36, pp.1681~1690 (1993)
21. Braun J, "The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis", Expert Opin Drug Saf, 16, pp.289~302 (2017)
22. Choy E, "Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX", Rheumatology(Oxford), 51, pp.1226~1234 (2012)
23. Goel N, "Certolizumab pegol", MAbs, 2, pp.137~147 (2010)
24. Wallis RS, "Tumour necrosis factor antagonists : structure, function, and tuberculosis risks", Lancet Infect Dis, 8, pp.601~611 (2008)
25. Baecklund E, "Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis", Arthritis Rheum, 54, pp.692~701 (2006)
26. Maneiro JR, "Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis : systematic review, meta-analysis, and network meta-analysis", Semin Arthritis Rheum, 47, pp.149~156 (2017)
27. Keystone EC, "Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis : results of a multicenter, randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 50, pp.353~363 (2004)
28. Ma X, "TNF inhibitor therapy for rheumatoid arthritis", Biomed Rep, 1, pp.177~184 (2013)
29. Kishimoto T, "IL-6 : from its discovery to clinical applications", Int Immunol, 22, pp.347~352 (2010)
30. Pop VV, "IL-6 roles-Molecular pathway and clinical implication in pancreatic cancer-A systemic review", Immunol Lett, 181, pp.45~50 (2017)
31. Rose-John S, "IL-6 trans-signaling : the heat is on", Immunity, 20, pp.2~4 (2004)
32. Jones SA, "Therapeutic strategies for the clinical blockade of IL-6", gp130 signaling, 2011, pp.121, 3375~3383
33. Mihara M, "Interleukin-6(IL-6)induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor", Br J Rheumatol, 34, pp.321~325 (1995)
34. Heink S, "Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells", Nat Immunol, 18, pp.74~85 (2017)
35. Alonzi T, "Interleukin 6 is required for the development of collagen-induced arthritis", J Exp Med, 187, pp.461~468 (1998)
36. Madhok R, "Serum interleukin 6 levels in rheumatoid arthritis : correlations with clinical and laboratory indices of disease activity", Ann Rheum Dis, 52, pp.232~234 (1993)
37. Sack U, "Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis", Rheumatol Int, 13, pp.45~51 (1993)
38. Korn T, "IL-17 and Th17 cells", Annu Rev Immunol, 27, pp.485~517 (2009)
39. Yoshida Y, "Interleukin 6 and rheumatoid arthritis", BioMed Res Int, 2014, pp.698313~ (2014)
40. Okamoto K, "Osteoimmunology", Cold Spring Harb Perspect Med, 9, pp.a031245~ (2019)
41. Shetty A, "Tocilizumab in the treatment of rheumatoid arthritis and beyond", Drug Des Devel Ther, 8, pp.349~364 (2014)
42. Nishimoto N, "Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody : a multicenter, double-blind, placebo-controlled trial", Arthritis Rheum, 50, pp.1761~1769 (2004)
43. McCarty D, "Efficacy and safety of sarilumab in patients with active rheumatoid arthritis", Ther Adv Musculoskelet Dis, 10, pp.61~67 (2018)
44. Mease PJ, "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a Phase IIb study of adults with active psoriatic arthritis", Arthritis Rheumatol, 68, pp.2163~2173 (2016)
45. Gabay C, "Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis(ADACTA) : a randomised, double-blind, controlled phase 4 trial", Lancet, 381, pp.1541~1550 (2013)
46. Burmester GR, "Low immunogenicity of tocilizumab in patients with rheumatoid arthritis", Ann Rheum Dis, 76, pp.1078~1085 (2017)
47. Kojima T, "Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis", Mod Rheumatol, 23, pp.977~985 (2013)
48. Scott LJ, "Tocilizumab : a review in rheumatoid arthritis", Drugs, 77, pp.1865~1879 (2017)
49. Abbas A, "Cellular and Molecular Immunology", pp.209~224 (2016), Elsevier
50. Sharpe AH, "T-cell costimulation--biology, therapeutic potential, and challenges", N Engl J Med, 355, pp.973~975 (2006)
51. Malmström V, "Modulating co-stimulation : a rational strategy in the treatment of rheumatoid arthritis", Arthritis Res Ther, 7(Suppl 2), pp.S15~S20 (2005)
52. Kremer JM, "Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis : a randomized trial", Ann Intern Med, 144, pp.865~876 (2006)
53. Genovese MC, "Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition", N Engl J Med, 353, pp.1114~1123 (2005)
54. SchiffM, "The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept : the ARRIVE trial", Ann Rheum Dis, 68, pp.1708~1714 (2009)
55. Scarsi M, "Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis", J Rheumatol, 41, pp.666~672 (2014)
56. Salmon JH, "Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice : results from the Orencia and Rheumatoid Arthritis(ORA)registry", Ann Rheum Dis, 75, pp.1108~1113 (2016)
57. SchiffM, "Efficacy and safety of abatacept or infliximab vs placebo in ATTEST : a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate", Ann Rheum Dis, 67, pp.1096~1103 (2008)
58. Martín Mola E, "Abatacept use in rheumatoid arthritis : evidence review and recommendations", Reumatol Clin, 9, pp.5~17 (2013)
59. Gu C, "IL-17 family : cytokines, receptors and signaling", Cytokine, 64, pp.477~485 (2013)
60. Toy D, "Cutting edge : interleukin 17 signals through a heteromeric receptor complex", J Immunol, 177, pp.36~39 (2006)
61. Ishigame H, "Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses", Immunity, 30, pp.108~119 (2009)
62. Chabaud M, "Human interleukin-17 : a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium", Arthritis Rheum, 42, pp.963~970 (1999)
63. Chabaud M, "Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis", Cytokine, 12, pp.1092~1099 (2000)
64. Yao Z, "Human IL-17 : a novel cytokine derived from T cells", J Immunol, 155, pp.5483~5486 (1995)
65. Haugeberg G, "Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis : results from 394 patients in the Oslo County Rheumatoid Arthritis register", Arthritis Rheum, 43, pp.522~530 (2000)
66. Koenders MI, "Induction of cartilage damage by overexpression of T cell interleukin-17A in experimental arthritis in mice deficient in interleukin-1", Arthritis Rheum, 52, pp.975~983 (2005)
67. Nakae S, "Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice", J Immunol, 171, pp.6173~6177 (2003)
68. Lubberts E, "Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion", Arthritis Rheum, 50, pp.650~659 (2004)
69. Langrish CL, "IL-23 drives a pathogenic T cell population that induces autoimmune inflammation", J Exp Med, 201, pp.233~240 (2005)
70. Hueber W, "Psoriasis Study Group Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis", Sci Transl Med, 2, pp.52~ (2010)
71. Genovese MC, "LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis : A phase I randomized, double-blind, placebo-controlled, proof-of-concept study", Arthritis Rheum, 62, pp.929~939 (2010)
72. Genovese MC, "Efficacy and safety of secukinumab in patients with rheumatoid arthritis : a phase II, dose-finding, double-blind, randomised, placebo controlled study", Ann Rheum Dis, 72, pp.863~869 (2013)
73. Tlustochowicz W, "Efficacy and safety of subcutaneous and intravenous loading dose regimens of secukinumab in patients with active rheumatoid arthritis : results from a randomized phase II study", J Rheumatol, 43, pp.495~503 (2016)
74. Blanco FJ, "Secukinumab in active rheumatoid arthritis : a phase III randomized, double-blind, active comparatorand placebo-controlled study", Arthritis Rheumatol, 69, pp.1144~1153 (2017)
75. Tahir H, "Secukinumab in active rheumatoid arthritis after anti-tnfα therapy : A randomized, double-blind placebocontrolled phase 3 study", Rheumatol Ther, 4, pp.475~488 (2017)
76. Benedetti G, "Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis", Eur J Immunol, 44, pp.339~347 (2014)
77. van Baarsen LG, "Heterogeneous expression pattern of interleukin 17A(IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis : possible explanation for nonresponse to anti-IL-17 therapy", Arthritis Res Ther, 16, pp.426~ (2014)
78. Roberts CA, "TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells", Front Immunol, 8, pp.157~ (2017)
79. Dinarello CA, "The IL-1 family of cytokines and receptors in rheumatic diseases", Nat Rev Rheumatol, 15, pp.612~632 (2019)
80. Noack M, "Selected cytokine pathways in rheumatoid arthritis", Semin Immunopathol, 39, pp.365~383 (2017)
81. Henderson B, "Comparison of the in vivo inflammatory activities after intra-articular injection of natural and recombinant IL-1 alpha and IL-1 beta in the rabbit", Biochem Pharmacol, 37, pp.4171~4176 (1988)
82. Pettipher ER, "Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint", Proc Natl Acad Sci U S A, 83, pp.8749~8753 (1986)
83. Ghivizzani SC, "Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee : implications for arthritis gene therapy", Gene Ther, 4, pp.977~982 (1997)
84. Ulfgren AK, "Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis : potential implications for treatment", Ann Rheum Dis, 59, pp.439~447 (2000)
85. Farrell SA, "Reframing social justice, feminism and abortion", Conscience, 26, pp.42~44 (2005)
86. Mertens M, "Anakinra for rheumatoid arthritis : a systematic review", J Rheumatol, 36, pp.1118~1125 (2009)
87. Gram H, "The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer", Pharmacol Res, 154, pp.104139~ (2020)
88. Genovese MC, "Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate", Arthritis Rheum, 50, pp.1412~1419 (2004)
89. Bresnihan B, "Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist", Arthritis Rheum, 41, pp.2196~2204 (1998)
90. Cohen S, "Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate : results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 46, pp.614~624 (2002)
91. Goldbach-Mansky R, "Blocking interleukin-1 in rheumatic diseases", Ann N Y Acad Sci, 1182, pp.111~123 (2009)
92. Hahn C, "The subendothelial extracellular matrix modulates JNK activation by flow", Circ Res, 104, pp.995~1003 (2009)
93. Sun Y, "Signaling pathway of MAPK", ERK in cell proliferation, differentiation, migration, senescence and apoptosis, 2015, pp.35, 600~604
94. Korb A, "Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritis", Arthritis Rheum, 54, pp.2745~2756 (2006)
95. Patterson H, "Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases", Clin Exp Immunol, 176, pp.1~10 (2014)
96. Meier FM, "Small-molecule therapeutics in rheumatoid arthritis : scientific rationale, efficacy and safety", Best Pract Res Clin Rheumatol, 28, pp.605~624 (2014)
97. Lee JC, "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis", Nature, 372, pp.739~746 (1994)
98. Shapiro L, "Osmotic regulation of cytokine synthesis in vitro", Proc Natl Acad Sci U S A, 92, pp.12230~12234 (1995)
99. Beyaert R, "The p38", RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor, 1996, pp.15, 1914~1923
100. Inoue T, "Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis", Proc Natl Acad Sci U S A, 103, pp.5484~5489 (2006)
101. Yoshizawa T, "Role of MAPK kinase 6 in arthritis : distinct mechanism of action in inflammation and cytokine expression", J Immunol, 183, pp.1360~1367 (2009)
102. Hegen M, "MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis", J Immunol, 177, pp.1913~1917 (2006)
103. O’Keefe SJ, "Chemical genetics define the roles of p38α and p38β in acute and chronic inflammation", J Biol Chem, 282, pp.34663~34671 (2007)
104. Badger AM, "Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis", Arthritis Rheum, 43, pp.175~183 (2000)
105. Nishikawa M, "Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653", Arthritis Rheum, 48, pp.2670~2681 (2003)
106. Kumar S, "p38 MAP kinases : key signalling molecules as therapeutic targets for inflammatory diseases", Nat Rev Drug Discov, 2, pp.717~726 (2003)
107. Cohen SB, "Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis", Arthritis Rheum, 60, pp.335~344 (2009)
108. Alten RE, "Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy", Ann Rheum Dis, 69, pp.364~367 (2010)
109. Branger J, "Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia", J Immunol, 168, pp.4070~4077 (2002)
110. Genovese MC, "A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis", J Rheumatol, 38, pp.846~854 (2011)
111. Damjanov N, "Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis : results of two randomized, double-blind, placebocontrolled clinical studies", Arthritis Rheum, 60, pp.1232~1241 (2009)
112. Genovese MC, "Inhibition of p38 : has the fat lady sung", Arthritis Rheum, 60, pp.317~320 (2009)
113. Kim C, "The kinase p38 α serves cell type-specific inflammatory functions in skin injury and coordinates proand anti-inflammatory gene expression", Nat Immunol, 9, pp.1019~1027 (2008)
114. Shaik SS, "Low intensity shear stress increases endothelial ELR+ CXC chemokine production via a focal adhesion kinase-p38β MAPK-NF-κB pathway", J Biol Chem, 284, pp.5945~5955 (2009)
115. Hammaker D, "“Go upstream, young man”: lessons learned from the p38 saga", Ann Rheum Dis, 69(Suppl 1), pp.i77~i82 (2010)
116. Wang C, "TAK1 is a ubiquitin-dependent kinase of MKK and IKK", Nature, 412, pp.346~351 (2001)
117. Fragoulis GE, "JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis", Rheumatology (Oxford), 58(Suppl 1), pp.i43~i54 (2019)
118. Seif F, "The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells", Cell Commun Signal, 15, pp.23~ (2017)
119. Harrington R, "JAK inhibitors in rheumatoid arthritis : An evidence-based review on the emerging clinical data", J Inflamm Res, 13, pp.519~531 (2020)
120. O’Shea JJ, "JAKs and STATs in immunity, immunodeficiency, and cancer", N Engl J Med, 368, pp.161~170 (2013)
121. Lee EB, "Tofacitinib versus methotrexate in rheumatoid arthritis", N Engl J Med, 370, pp.2377~2386 (2014)
122. Fleischmann R, "Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis(ORAL Strategy) : a phase 3b", 4, double-blind, head-tohead, randomised controlled trial, 2017, pp.390, 457~468
123. Fleischmann R, "Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment", Arthritis Rheumatol, 69, pp.506~517 (2017)
124. Taylor PC, "Baricitinib versus placebo or adalimumab in rheumatoid arthritis", N Engl J Med, 376, pp.652~662 (2017)
125. Parmentier JM, "In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib(ABT-494)", BMC Rheumatol, 2, pp.23~ (2018)
126. Conaghan PG, "Upadacitinib in rheumatoid arthritis : A benefit-risk assessment across a Phase III program", Drug Saf, 44, pp.515~530 (2021)
127. Burja B, "Hi-JAKi-ng synovial fibroblasts in inflammatory arthritis with JAK inhibitors", Front Med(Lausanne), 7, pp.124~ (2020)

관련 논문AI추천